Nilotinib in Parkinson's disease: A systematic review and meta-analysis

BACKGROUND: Nilotinib, which inhibits cellular Abelson tyrosine kinase, may be an effective treatment for patients with Parkinson's disease (PD). The purpose of this study is to evaluate the outcomes of different doses of nilotinib in patients with PD. METHODS: We searched PubMed, Embase, Web o...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xiaolu, Yuan, Ping, Kou, Liqiu, Chen, Xiu, Li, Jun, Li, Yaling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Aging Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558096/
https://www.ncbi.nlm.nih.gov/pubmed/36248007
http://dx.doi.org/10.3389/fnagi.2022.996217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558096/
https://www.ncbi.nlm.nih.gov/pubmed/36248007
http://dx.doi.org/10.3389/fnagi.2022.996217

Ejemplares similares